Company Valuation: GlaxoSmithKline Pakistan Limited

Data adjusted to current consolidation scope
Fiscal Period: December 2024 2025 2026 2027 2028
Market Cap 1 126,403 124,132 108,419 - -
Change - -1.8% -12.66% - -
Enterprise Value (EV) 126,403 124,132 108,419 108,419 108,419
Change - -1.8% -12.66% 0% 0%
P/E 19.3x 12.4x 9.88x 8.43x 7.52x
PBR - 3.69x 2.49x 2.15x 1.88x
PEG - 0.2x 1.04x 0.5x 0.6x
Capitalization / Revenue - 1.88x 1.58x 1.45x 1.33x
EV / Revenue - 0x 1.58x 1.45x 1.33x
EV / EBITDA - - - - -
EV / EBIT - - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Dividend per Share 2 - 17 18.37 20.81 23.5
Rate of return - 4.36% 5.4% 6.11% 6.9%
EPS 2 20.52 31.48 34.47 40.39 45.27
Distribution rate - 54% 53.3% 51.5% 51.9%
Net sales 1 - 65,901 68,813 74,577 81,779
EBITDA - - - - -
EBIT - - - - -
Net income 1 6,536 10,025 10,490 12,420 14,268
Net Debt - - - - -
Reference price 2 396.91 389.78 340.44 340.44 340.44
Nbr of stocks (in thousands) 318,467 318,467 318,467 - -
Announcement Date 24/03/25 26/03/26 - - -
1PKR in Million2PKR
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
9.88x - - 5.4% 391M
36.57x13.2x26.79x0.54% 1,141B
30.41x - - 1.96% 659B
33.95x7.85x16.34x2.58% 470B
20.47x4.85x12.03x2.72% 366B
22.39x5.8x14.38x2.75% 302B
21x4.33x12.29x2.03% 254B
27.98x7.21x12.8x2.28% 239B
13.62x4.84x10.15x3.77% 207B
-45.1x6.51x25.42x2.23% 183B
Average 17.12x 6.82x 16.27x 2.63% 382.14B
Weighted average by Cap. 25.80x 8.63x 18.95x 1.88%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Valuation GlaxoSmithKline Pakistan Limited